A Repeat Dose Positron Emission Tomography Study With GSK1144814

GSK1144814 is a dual Neurokinin 1 and Neurokinin 3 antagonist with the potential to treat schizophrenia and depression. This study described in the present protocol consists of two parts. Part A is a multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ascending doses of GSK1144814. The study is a single blind, randomised, placebo controlled design in healthy male and female (of non childbearing potential) subjects. Part B is an open label design in healthy male subjects to assess the GSK1144814 Neurokinin 1 receptor occupancy after repeat oral dosing by positron emission tomography scanning with \[11C\] GR205171.